The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.

Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business. 

Researchers have made it a priority to learn as much about the durability of TAVR valves as possible. A new study in JACC: Cardiovascular Interventions used updated VARC-3 definitions to identify signs of hemodynamic valve deterioration in nearly 2,500 patients.

Meril Life Sciences has been manufacturing its Myval heart valves for years. The devices are approved and available in both India and Europe, but they have not been approved by the FDA.

It looked like the wildfires in Los Angeles could force STS to cancel its annual meeting, but the group worked with city officials and was able to carry on as planned. STS President Jennifer C. Romano, MD, MS, discussed that difficult decision and previewed the three-day event in a new interview.

Rakesh Gopinathannair, MD, lead author of a recent American Heart Association scientific statement on cardiac arrhythmias associated with COVID-19, reviewed the latest science associated with this important topic.

Excessive stress may still be harmful to a surgeon's performance, researchers warned, but moderate stress early on during a procedure appears to reduce the odds of a major complication. 

Stephen Browning, the FDA's assistant director of hemodynamics and heart failure diagnostics, spoke with Cardiovascular Business about the agency's perspective on AI-enabled cardiovascular devices and many other topics.